Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 235, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2022.114240
Keywords
Chemoinformatics search; PPAR pan-agonist; Docking experiments; Glucose uptake
Categories
Funding
- Universita degli Studi di Bari Aldo Moro
Ask authors/readers for more resources
This article presents a chemoinformatics search approach for identifying new ligands as PPAR pan-agonists. The identified compound has attractive activity profile in reducing lipid accumulation and improving insulin sensitivity, making it a potential lead for the treatment of dyslipidemic type 2 diabetes.
The peroxisome proliferator-activated receptors (PPARs) are nuclear receptors involved in the regulation of the metabolic homeostasis and therefore represent valuable therapeutic targets for the treatment of metabolic diseases. The development of more balanced drugs interacting with PPARs, devoid of the side-effects showed by the currently marketed PPAR gamma full agonists, is considered the major challenge for the pharmaceutical companies. Here we present a chemoinformatics search approach for new ligands that let us identify a novel PPAR pan-agonist with a very attractive activity profile being able to reduce lipid accumulation and improve insulin sensitivity. This compound represents, therefore, the potential lead of a new class of drugs for treatment of dyslipidemic type 2 diabetes. (C) 2022 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available